RESUMEN
AIM: To enhance drug targeting and blood-brain barrier penetration for Parkinson's disease (PD), a novel nanoscale magnetic nimodipine (NMD) delivery system was designed and prepared. MATERIALS & METHODS: The PD rats were established and treated with free NMD or Fe3O4-modified NMD liposomes (Fe3O4-NMD-lips). Then, factional anisotropy values were measured by MRI to evaluate therapy efficacy. RESULTS: Fe3O4-NMD-lips showed the best neuroprotective effect, and the NMD concentration of lesions was 2.5-fold higher in Fe3O4-NMD-lips group than that of free NMD group. CONCLUSION: These results demonstrated that the magnetic drug system had a great potential to cross the blood-brain barrier and provided a noninvasive and effective therapeutic strategy for PD.
Asunto(s)
Liposomas/química , Nanopartículas de Magnetita/química , Fármacos Neuroprotectores/administración & dosificación , Nimodipina/administración & dosificación , Enfermedad de Parkinson/tratamiento farmacológico , Animales , Barrera Hematoencefálica/metabolismo , Sistemas de Liberación de Medicamentos , Liberación de Fármacos , Estabilidad de Medicamentos , Humanos , Imagen por Resonancia Magnética , Terapia Molecular Dirigida , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/química , Nimodipina/efectos adversos , Nimodipina/química , Enfermedad de Parkinson/diagnóstico por imagen , Ratas , Distribución TisularRESUMEN
In the study, a new photoresponsive nano drug delivery system was developed by encapsulating indocyanine green into liposomes (ICG-liposomal wedelolactone), which could improve the water solubility and bioavailability of wedelolactone. The hyperthermia, produced by ICG under near-infrared (NIR) light irradiation, promoted wedelolactone release rapidly from the carriers. The release amount of ICG-liposomal wedelolactone under NIR irradiation reached up to 96.74% over 8h, achieving the drug of on-demand release. Moreover, the growth of HepG2 cells was obviously inhibited by ICG-liposomal wedelolactone under NIR, and the early apoptotic rate of HepG2 cells was 33.74%. The tumor inhibition rate was 81% in the mice bearing tumor treated with the drug system. The results proved that ICG-liposomal wedelolactone, as a novel drug delivery system to co-delivery chemotherapeutic agents and photothermal agents, achieved synergetic effect of chemotherapy and photothermotherapy, which will have an enormous potential in future cancer therapy.